Adjuvant chemotherapy for breast cancer--30 years later

DOI: 10.1056/nejme068204
New England Journal of Medicine, 2006, 355, 1920-2.

#	Paper	IF	Citations
40	Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. *Journal of the National Cancer Institute*, **2007**, 99, 506-15	9.7	28
39	Identifying and hurdling obstacles to translational research. *Nature Reviews Immunology*, **2007**, 7, 77-82	36.5	34
38	UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. *Surgery Today*, **2007**, 37, 923-43	3	25
37	Adjuvante chemotherapie bij mammacarcinoom. *Medisch-farmaceutische Mededelingen*, **2007**, 45, 76-76		
36	Differences in breast cancer diagnosis and treatment: experiences of insured and uninsured women in a safety-net setting. *Inquiry (United States)*, **2008**, 45, 323-39	1.4	15
35	Differences in Breast Cancer Diagnosis and Treatment:Experiences of Insured and Uninsured Patients in a Safety Net Setting. **2008**,		1
34	Troglitazone reverses the multiple drug resistance phenotype in cancer cells. *Drug Design, Development and Therapy*, **2009**, 3, 79-88	4.4	14
33	Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin. *Open Medicine (Poland)*, **2009**, 4, 327-330	2.2	
32	Breast Cancer. 223-253		
31	Adjuvant chemotherapy in young women with breast cancer. *Breast Cancer Research and Treatment*, **2010**, 123 Suppl 1, 39-41	4.4	115
30	Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 77-82	2.2	115
29	MYC in oncogenesis and as a target for cancer therapies. *Advances in Cancer Research*, **2010**, 107, 163-224	5.9	175
28	Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. *BMC Neuroscience*, **2011**, 12, 124	3.2	82
27	High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer. *British Journal of Cancer*, **2011**, 105, 1480-6	8.7	5
26	The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. *Arzneimittelforschung*, **2012**, 62, 525-31		53
25	Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. *Journal of Clinical Oncology*, **2012**, 30, 1080-6	2.2	307
24	Neutrophil dynamics after chemotherapy and G-CSF: the role of pharmacokinetics in shaping the response. *Journal of Theoretical Biology*, **2012**, 315, 97-109	2.3	28

23	The influence of non-clinical patient factors on medical oncologists' decisions to recommend breast cancer adjuvant chemotherapy. *Breast Cancer Research and Treatment*, **2012**, 134, 867-74	4.4	2
22	Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies. *Molecular Biology Reports*, **2012**, 39, 5161-8	2.8	15
21	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. *BMC Cancer*, **2013**, 13, 163	4.8	24
20	Selenium nanoparticle-enriched Lactobacillus brevis causes more efficient immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. *DARU, Journal of Pharmaceutical Sciences*, **2013**, 21, 33	3.9	66
19	Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. *Critical Reviews in Oncology/Hematology*, **2013**, 88, 87-101	7	53
18	Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients. *Breast*, **2013**, 22, 926-32	3.6	3
17	Ways of Regulating Drugs in the 19th and 20th Centuries. **2013**,		14
16	Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. *Blood*, **2013**, 121, 2996-3004	2.2	152
15	Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens. *Journal of Clinical Nursing*, **2014**, 23, 2757-68	3.2	12
14	Breast cancer. **2014**, 237-274		2
13	Sequential Dose-dense 5-fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel in Patients with Early Breast Cancer with Four or more Positive Lymph Nodes. *Tumori*, **2014**, 100, 128-135	1.7	1
12	Extended Versus Standard Lymphadenectomy for Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials. *Journal of Gastrointestinal Surgery*, **2015**, 19, 1725-32	3.3	43
11	Retracted: Involvement of insulin-like growth factor-1 in chemotherapy-related cognitive impairment. *Behavioural Brain Research*, **2015**, 279, 112-22	3.4	5
10	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. *Clinical Breast Cancer*, **2018**, 18, 53-62.e3	3	5
9	Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy. *Breast Cancer*, **2018**, 25, 723-728	3.4	1
8	Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. *Future Oncology*, **2019**, 15, 1781-1789	3.6	0
7	The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. *PLoS ONE*, **2013**, 8, e67589	3.7	18
6	Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. *PLoS ONE*, **2015**, 10, e0133569	3.7	75

5	Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model. *Iranian Journal of Biotechnology*, **2015**, 13, 1-9	1	20
4	Early Diagnosis of Cardiac Toxicity Related to Antineoplastic Treatment. *Journal of Cancer Therapy*, **2011**, 02, 161-166	0.2	4
3	What's in a Pill? On the Informational Enrichment of Anti-Cancer Drugs. **2013**, 181-205		
2	A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. *Therapeutics and Clinical Risk Management*, **2007**, 3, 665-73	2.9	14
1	Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.. *Molecular Therapy*, **2022**,	11.7	0